Compare COCP & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCP | LEXX |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | Canada |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 16.2M |
| IPO Year | 2011 | N/A |
| Metric | COCP | LEXX |
|---|---|---|
| Price | $1.02 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $1.50 |
| AVG Volume (30 Days) | 34.1K | ★ 131.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 8.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,712,091.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $601.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.86 | $0.46 |
| 52 Week High | $2.19 | $1.90 |
| Indicator | COCP | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 53.39 | 48.50 |
| Support Level | $1.00 | $0.58 |
| Resistance Level | $1.11 | $0.83 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 53.30 | 40.90 |
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.